BKBaktash Khozoee

Baktash Khozoee

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Baktash Khozoee has a total of 107 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Mycobacterium tuberculosis complex strain discordance among people with tuberculosis and a history of household contact: a systematic review and meta-analysis

    by Tom A Yates, Martha Chipinduro, Robert W Aldridge, Baktash Khozoee, Joanne R Winter, Frank Tanser, Ibrahim Abubakar, Katharina Kranzer

  • Open Access

    Development of clinical immunity to Plasmodium vivax following repeat controlled human malaria infection

    by Mimi M. Hou, Adam C. Harding, Natalie M. Barber, Prasun Kundu, Florian A. Bach, Jo Salkeld, Yrene Themistocleous, Nicola M. Greenwood, Jee-Sun Cho, Jordan R. Barrett, et al.

    Clinical immunity to malaria can lead to asymptomatic infection, but the underlying mechanisms remain unclear. To examine the development of clinical immunity, we conducted a multi-cohort, repeat controlled human malaria infection (CHMI) study with Plasmodium vivax, and a heterologous rechallenge with P. falciparum (ClinicalTrials.gov NCT03797989). Malaria-naïve adults underwent CHMI up to three times, by administration of red blood cells infected with P. vivax PvW1 clone or P. falciparum 3D7 clone. Nineteen participants underwent primary CHMI with P. vivax, 12 returned for secondary homologous CHMI and 2 for tertiary homologous CHMI. Six participants who had completed P. vivax CHMI then underwent heterologous rechallenge with P. falciparum. We find that clinical immunity to P. vivax develops rapidly after a single CHMI, protecting participants against fever and laboratory abnormalities. This is underpinned by the attenuation of inflammatory cytokines and chemokines, as well as reduced coagulation and endothelium activation. In contrast, there is no evidence of anti-parasite immunity, suggesting that mechanisms of clinical immunity can operate independently of pathogen load to reduce the damage caused by malaria infection. In addition, we show that clinical immunity to P. vivax is parasite species-specific and provides no protection against CHMI with P. falciparum.


  • Open Access

    Vaccination with Plasmodium vivax Duffy-binding protein inhibits parasite growth during controlled human malaria infection

    by Mimi M. Hou, Jordan R. Barrett, Yrene Themistocleous, Thomas A. Rawlinson, Ababacar Diouf, Francisco J. Martinez, Carolyn M. Nielsen, Amelia M. Lias, Lloyd D. W. King, Nick J. Edwards, et al.

    There are no licensed vaccines against Plasmodium vivax . We conducted two phase 1/2a clinical trials to assess two vaccines targeting P. vivax Duffy-binding protein region II (PvDBPII). Recombinant viral vaccines using chimpanzee adenovirus 63 (ChAd63) and modified vaccinia virus Ankara (MVA) vectors as well as a protein and adjuvant formulation (PvDBPII/Matrix-M) were tested in both a standard and a delayed dosing regimen. Volunteers underwent controlled human malaria infection (CHMI) after their last vaccination, alongside unvaccinated controls. Efficacy was assessed by comparisons of parasite multiplication rates in the blood. PvDBPII/Matrix-M, given in a delayed dosing regimen, elicited the highest antibody responses and reduced the mean parasite multiplication rate after CHMI by 51% ( n = 6) compared with unvaccinated controls ( n = 13), whereas no other vaccine or regimen affected parasite growth. Both viral-vectored and protein vaccines were well tolerated and elicited expected, short-lived adverse events. Together, these results support further clinical evaluation of the PvDBPII/Matrix-M P. vivax vaccine.


  • Open Access

    Increased imported severe Plasmodium falciparum malaria involving hyperparasitaemia (>10%) in a UK hospital following relaxation of COVID-19 restrictions compared to the pre-pandemic period

    by Bennett Choy, Henrietta Bristowe, Baktash Khozoee, Temi Lampejo

    Malaria remains a major cause of morbidity and mortality with an estimated 241 million cases and 627 000 deaths (96% of which occurred in Africa) in 2020; a significant proportion (estimated at over two-thirds) of these deaths have been attributed to coronavirus disease 2019 (COVID-19) pandemic-associated disruptions. 1 In view of COVID-19 public health measures including travel restrictions, major declines in travel-related malaria cases have occurred over the course of the COVID-19 pandemic. 2–4 The impact of the more recent relaxation of COVID-19 restrictions on travel-associated malaria remains to be fully elucidated. A significant increase in cases of severe imported malaria cases was observed in Spain in 2021 following partial relaxation of COVID-19 restrictions (trends or differences in parasitaemias/hyperparasitaemia rates over the course of the study period were not reported). 5 The UK completely removed all COVID-19-associated restrictions on international travel in March 2022 (one of the first countries to do so). We sought to investigate whether following the removal of these travel restrictions the rate of severe imported Plasmodium falciparum malaria and/or the rate of hyperparasitaemia, defined by the World Health Organisation (WHO) as P. falciparum parasitaemia >10% and which indicates severe malaria in all settings, differed significantly when compared to the pre-pandemic period. 6


  • Open Access

    Impact of a blood-stage vaccine on Plasmodium vivax malaria

    by Mimi M. Hou, Jordan R. Barrett, Yrene Themistocleous, Thomas A. Rawlinson, Ababacar Diouf, Francisco J. Martinez, Carolyn M. Nielsen, Amelia M. Lias, Lloyd D. W. King, Nick J. Edwards, et al.

    Background: There are no licensed vaccines against Plasmodium vivax , the most common cause of malaria outside of Africa. Methods: We conducted two Phase I/IIa clinical trials to assess the safety, immunogenicity and efficacy of two vaccines targeting region II of P. vivax Duffy-binding protein (PvDBPII). Recombinant viral vaccines (using ChAd63 and MVA vectors) were administered at 0, 2 months or in a delayed dosing regimen (0, 17, 19 months), whilst a protein/adjuvant formulation (PvDBPII/Matrix-M™) was administered monthly (0, 1, 2 months) or in a delayed dosing regimen (0, 1, 14 months). Delayed regimens were due to trial halts during the COVID-19 pandemic. Volunteers underwent heterologous controlled human malaria infection (CHMI) with blood-stage P. vivax parasites at 2-4 weeks following their last vaccination, alongside unvaccinated controls. Efficacy was assessed by comparison of parasite multiplication rate (PMR) in blood post-CHMI, modelled from parasitemia measured by quantitative polymerase-chain-reaction (qPCR). Results: Thirty-two volunteers were enrolled and vaccinated (n=16 for each vaccine). No safety concerns were identified. PvDBPII/Matrix-M™, given in the delayed dosing regimen, elicited the highest antibody responses and reduced the mean PMR following CHMI by 51% (range 36-66%; n=6) compared to unvaccinated controls (n=13). No other vaccine or regimen impacted parasite growth. In vivo growth inhibition of blood-stage P. vivax correlated with functional antibody readouts of vaccine immunogenicity. Conclusions: Vaccination of malaria-naïve adults with a delayed booster regimen of PvDBPII/ Matrix-M™ significantly reduces the growth of blood-stage P. vivax . Funded by the European Commission and Wellcome Trust; VAC069, VAC071 and VAC079 ClinicalTrials.gov numbers NCT03797989 , NCT04009096 and NCT04201431 .


  • Open Access

    Controlled human malaria infection with a clone of Plasmodium vivax with high-quality genome assembly

    by Angela M. Minassian, Yrene Themistocleous, Sarah E. Silk, Jordan R. Barrett, Alison Kemp, Doris Quinkert, Carolyn M. Nielsen, Nick J. Edwards, Thomas A. Rawlinson, Fernando Ramos Lopez, et al.

    Controlled human malaria infection (CHMI) provides a highly informative means to investigate host-pathogen interactions and enable in vivo proof-of-concept efficacy testing of new drugs and vaccines. However, unlike Plasmodium falciparum , well-characterized P . vivax parasites that are safe and suitable for use in modern CHMI models are limited. Here, 2 healthy malaria-naive United Kingdom adults with universal donor blood group were safely infected with a clone of P . vivax from Thailand by mosquito-bite CHMI. Parasitemia developed in both volunteers, and prior to treatment, each volunteer donated blood to produce a cryopreserved stabilate of infected RBCs. Following stringent safety screening, the parasite stabilate from one of these donors (PvW1) was thawed and used to inoculate 6 healthy malaria-naive United Kingdom adults by blood-stage CHMI, at 3 different dilutions. Parasitemia developed in all volunteers, who were then successfully drug treated. PvW1 parasite DNA was isolated and sequenced to produce a high-quality genome assembly by using a hybrid assembly method. We analyzed leading vaccine candidate antigens and multigene families, including the vivax interspersed repeat (VIR) genes, of which we identified 1145 in the PvW1 genome. Our genomic analysis will guide future assessment of candidate vaccines and drugs, as well as experimental medicine studies.